Literature DB >> 10100025

Fatal multi-organ failure after suicidal overdose with MDMA, 'ecstasy': case report and review of the literature.

A Walubo1, D Seger.   

Abstract

A 53-year-old prisoner died of multiorgan failure after a suicidal overdose with 3,4-methylenedeoxymethamphetamine (MDMA, 'Ecstasy'). Twelve hours after ingestion of MDMA, the patient became severely hyperthermic (107.2 degrees F) with evidence of rhabdomyolysis. He subsequently developed acute respiratory distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC) and acute renal failure. At autopsy, plasma concentration of MDMA was 3.05 mg/L. This case shows that MDMA is still abused in our community and clinicians should know the symptoms of MDMA intoxication. In particular, MDMA should be considered when patients have symptoms or signs of increased sympathetic activity. The pathophysiology and treatment of MDMA-induced hyperthermia are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100025     DOI: 10.1177/096032719901800209

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  14 in total

Review 1.  Street drug abuse leading to critical illness.

Authors:  Babak Mokhlesi; Prasad S Garimella; Aaron Joffe; Valerie Velho
Journal:  Intensive Care Med       Date:  2004-03-04       Impact factor: 17.440

2.  An announced suicide with ecstasy.

Authors:  Kathrin Libiseller; Marion Pavlic; Petra Grubwieser; Walter Rabl
Journal:  Int J Legal Med       Date:  2005-09-21       Impact factor: 2.686

Review 3.  The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

Authors:  H Kalant
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

Review 4.  Accidental and iatrogenic causes of acute kidney injury.

Authors:  Katherine Twombley; Michel Baum; Jyothsna Gattineni
Journal:  Curr Opin Pediatr       Date:  2011-04       Impact factor: 2.856

5.  Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma.

Authors:  Melanie Mueller; Erin A Kolbrich-Spargo; Frank T Peters; Marilyn A Huestis; George A Ricaurte; Hans H Maurer
Journal:  Anal Bioanal Chem       Date:  2009-01-30       Impact factor: 4.142

6.  Transient proximal tubular renal injury following Ecstasy ingestion.

Authors:  Charles Kwon; Arno Zaritsky; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2003-05-28       Impact factor: 3.714

7.  Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage.

Authors:  Melanie Mueller; Frank T Peters; Marilyn A Huestis; George A Ricaurte; Hans H Maurer
Journal:  Forensic Sci Int       Date:  2009-01-07       Impact factor: 2.395

8.  Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with alpha1- plus beta3-adrenoreceptor antagonists.

Authors:  Jon E Sprague; Robert E Brutcher; Edward M Mills; David Caden; Daniel E Rusyniak
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

9.  Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma.

Authors:  Melanie Mueller; Frank T Peters; George A Ricaurte; Hans H Maurer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-07-06       Impact factor: 3.205

10.  Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat.

Authors:  Marta Concheiro; Michael H Baumann; Karl B Scheidweiler; Richard B Rothman; Gina F Marrone; Marilyn A Huestis
Journal:  Drug Metab Dispos       Date:  2013-10-18       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.